Puma Biotechnology, Inc. PBYI NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

69/100

4/7 Pass

SharesGrow Intrinsic Value

Puma Biotechnology, Inc. (PBYI) 产生了 $14.42M 经营性现金流截至季度 2025-12-31. 扣除资本支出 $36K, 自由现金流为 $14.46M.

自由现金流利润率为 19.1% 佔营收. 现金转換率为 1.22x, 表明盈利有现金支撐.

本页支持的标准:

HEALTH (83/100, Pass) — 表明公司能够轻鬆償还债务
MOAT (54/100, Partial) — 现金流产生能力存在但未达到寬护城河水准
INCOME (55/100) — 现金转換率为 1.22x 确认盈利有真实现金流支撐

SharesGrow 收入评分: 69/100 其中 4/7 项标准通过.

SharesGrow 7-Criteria Score

69/100

SG Score

View full scorecard →

✓

价值

95/100

Price-to-Earnings & upside

→ Valuation

✗

未來

20/100

Analyst consensus

→ Forecast

✓

过去

100/100

→ Income

✓

健康

83/100

Debt-to-Equity & liquidity

Proven by this page

护城河

54/100

Proven by this page

✓

成长

73/100

→ Income

收入

55/100

→ Income

Puma Biotechnology, Inc. 现金流量历史

指标	TTM	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Operating Cash Flow	$41.8M	$14.42M	$9.69M	$14.08M	$3.61M
资本支出	$-71K	$36K	$-26K	$-20K	$-61K
Free Cash Flow	$41.73M	$14.46M	$9.66M	$14.06M	$3.55M

其他人也在看

RVMD

Revolution Medicines, Inc.

$152.54

+3.76%

MDGL

Madrigal Pharmaceuticals, Inc.

$518.58

-1.22%

PTCT

PTC Therapeutics, Inc.

$73.57

+0.77%

CRNX

Crinetics Pharmaceuticals, Inc.

$39.77

+0.05%

VKTX

Viking Therapeutics, Inc.

$35.45

-0.20%

RARE

Ultragenyx Pharmaceutical Inc.

$25.18

+2.48%

SRPT

Sarepta Therapeutics, Inc.

$21.73

-1.90%

IOVA

Iovance Biotherapeutics, Inc.

$3.82

+4.95%

Puma Biotechnology, Inc. PBYI NASDAQ

其他人也在看

获取低估股票提醒